PLoS ONE (Jan 2012)

Associations between XPD Asp312Asn polymorphism and risk of head and neck cancer: a meta-analysis based on 7,122 subjects.

  • Yuan Yuan Hu,
  • Hua Yuan,
  • Guang Bing Jiang,
  • Ning Chen,
  • Li Wen,
  • Wei Dong Leng,
  • Xian Tao Zeng,
  • Yu Ming Niu

DOI
https://doi.org/10.1371/journal.pone.0035220
Journal volume & issue
Vol. 7, no. 4
p. e35220

Abstract

Read online

BackgroundTo investigate the association between XPD Asp312Asn polymorphism and head and neck cancer risk through this meta-analysis.MethodsWe performed a meta-analysis of 9 published case-control studies including 2,670 patients with head and neck cancer and 4,452 controls. An odds ratio (OR) with a 95% confidence interval (CI) was applied to assess the association between XPD Asp312Asn polymorphism and head and neck cancer risk.ResultsOverall, no significant association between XPD Asp312Asn polymorphism and head and neck cancer risk was found in this meta-analysis (Asn/Asn vs. Asp/Asp: OR = 0.95, 95%CI = 0.80-1.13, P = 0.550, P(heterogeneity) = 0.126; Asp/Asn vs. Asp/Asp: OR = 1.11, 95%CI = 0.99-1.24, P = 0.065, P(heterogeneity) = 0.663; Asn/Asn+Asp/Asn vs. Asp/Asp: OR = 1.07, 95%CI = 0.97-1.19, P = 0.189, P(heterogeneity) = 0.627; Asn/Asn vs. Asp/Asp+Asp/Asn: OR = 0.87, 95%CI = 0.68-1.10, P = 0.243, P(heterogeneity) = 0.089). In the subgroup analysis by HWE, ethnicity, and study design, there was still no significant association detected in all genetic models.ConclusionsThis meta-analysis demonstrates that XPD Asp312Asn polymorphism may not be a risk factor for developing head and neck cancer.